Theophylline - Cyrano Therapeutics
Alternative Names: CRY 064; CYR-064Latest Information Update: 20 Oct 2023
At a glance
- Originator Cyrano Therapeutics
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Xanthines
- Mechanism of Action Phosphoric diester hydrolase inhibitors; Purinergic P1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Anosmia
- Preclinical Taste disorders
Most Recent Events
- 12 Oct 2023 Phase-II FLAVOR clinical trials in Anosmia in USA (Intranasal) (NCT06019000)
- 18 Jan 2023 Cyrano Therapeutics plans a phase II trial for Post-viral smell loss in USA (Intranasal, Spray) in second quarter of 2023
- 18 Jan 2023 US FDA approves IND application for theophylline in Taste disorders